Rocket Pharmaceuticals, a late-stage, clinical biotechnology company, completed the acquisition of Renovacor, a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, for $53m. "The acquisition of Renovacor aligns with our strategy to expand our leadership position in AAV-based gene therapy for cardiac disease and gives us a perfect opportunity to continue on our mission to transform the lives of heart failure patients through the power of gene therapy," Gaurav Shah, Rocket CEO.